Cargando…

Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report

BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacella, Fernanda, Agostinelli, Enzo, Carlesimo, Sandra Cinzia, Nebbioso, Marcella, Secondi, Roberto, Forastiere, Michele, Pacella, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062904/
https://www.ncbi.nlm.nih.gov/pubmed/27733187
http://dx.doi.org/10.1186/s13256-016-1077-2
_version_ 1782459871920128000
author Pacella, Fernanda
Agostinelli, Enzo
Carlesimo, Sandra Cinzia
Nebbioso, Marcella
Secondi, Roberto
Forastiere, Michele
Pacella, Elena
author_facet Pacella, Fernanda
Agostinelli, Enzo
Carlesimo, Sandra Cinzia
Nebbioso, Marcella
Secondi, Roberto
Forastiere, Michele
Pacella, Elena
author_sort Pacella, Fernanda
collection PubMed
description BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber. CASE PRESENTATION: An 83-year-old white woman presented to our Emergency Unit complaining of pain and vision loss in herright eye lasting a week. Her anamnesis revealed a history of persistent cystoid macular edema after phacoemulsification with scleral-fixated posterior chamber intraocular lens implantation, recently treated with an intravitreal Ozurdex implant. She also took a long-distance flight 2 days after the injection. An anterior segment examination showed corneal edema and the rod implant adherent to corneal endothelium. To avoid corneal decompensation, we opted for a implant repositioning. Under topical anesthesia, a 30-gauge needle was introduced through a limbar incisionto mobilize the dislocated rod. Balanced saline solution was injected, with a successful repositioning of the implant into the vitreous cavity. Topical 5 % hypertonic saline solution and 0.2 % betamethasone associated with 0.5 % chloramphenicol drops were administered four times a day. To prevent redislocation of the Ozurdex implant, she was instructed to avoid prone position, any kind of physical effort, and not to undertake long-distance flights during the first postoperative week. One week after surgery, an anterior segment examination showed an improvement of corneal edema. Funduscopy showed that the Ozurdex implant was settled into the vitreous cavity. CONCLUSIONS: Anterior chamber dislocation of Ozurdex from the vitreous cavity is rare. In our patient, in addition to the posterior capsule tearing, the long-distance flight could have contributed to implant dislocation. Repositioning of the implant is necessary to avoid endothelial decompensation. It can be carried out by using saline balanced solution with the same efficacy as other surgical procedures reported in the literature. A possible disadvantage of this procedure could be implant migration.
format Online
Article
Text
id pubmed-5062904
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50629042016-10-24 Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report Pacella, Fernanda Agostinelli, Enzo Carlesimo, Sandra Cinzia Nebbioso, Marcella Secondi, Roberto Forastiere, Michele Pacella, Elena J Med Case Rep Case Report BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber. CASE PRESENTATION: An 83-year-old white woman presented to our Emergency Unit complaining of pain and vision loss in herright eye lasting a week. Her anamnesis revealed a history of persistent cystoid macular edema after phacoemulsification with scleral-fixated posterior chamber intraocular lens implantation, recently treated with an intravitreal Ozurdex implant. She also took a long-distance flight 2 days after the injection. An anterior segment examination showed corneal edema and the rod implant adherent to corneal endothelium. To avoid corneal decompensation, we opted for a implant repositioning. Under topical anesthesia, a 30-gauge needle was introduced through a limbar incisionto mobilize the dislocated rod. Balanced saline solution was injected, with a successful repositioning of the implant into the vitreous cavity. Topical 5 % hypertonic saline solution and 0.2 % betamethasone associated with 0.5 % chloramphenicol drops were administered four times a day. To prevent redislocation of the Ozurdex implant, she was instructed to avoid prone position, any kind of physical effort, and not to undertake long-distance flights during the first postoperative week. One week after surgery, an anterior segment examination showed an improvement of corneal edema. Funduscopy showed that the Ozurdex implant was settled into the vitreous cavity. CONCLUSIONS: Anterior chamber dislocation of Ozurdex from the vitreous cavity is rare. In our patient, in addition to the posterior capsule tearing, the long-distance flight could have contributed to implant dislocation. Repositioning of the implant is necessary to avoid endothelial decompensation. It can be carried out by using saline balanced solution with the same efficacy as other surgical procedures reported in the literature. A possible disadvantage of this procedure could be implant migration. BioMed Central 2016-10-13 /pmc/articles/PMC5062904/ /pubmed/27733187 http://dx.doi.org/10.1186/s13256-016-1077-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Pacella, Fernanda
Agostinelli, Enzo
Carlesimo, Sandra Cinzia
Nebbioso, Marcella
Secondi, Roberto
Forastiere, Michele
Pacella, Elena
Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title_full Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title_fullStr Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title_full_unstemmed Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title_short Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
title_sort management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062904/
https://www.ncbi.nlm.nih.gov/pubmed/27733187
http://dx.doi.org/10.1186/s13256-016-1077-2
work_keys_str_mv AT pacellafernanda managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT agostinellienzo managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT carlesimosandracinzia managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT nebbiosomarcella managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT secondiroberto managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT forastieremichele managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport
AT pacellaelena managementofanteriorchamberdislocationofadexamethasoneintravitrealimplantacasereport